ACS GCI Pharmaceutical Roundtable

In 2005, the ACS Green Chemistry Institute^® (ACS GCI) and global pharmaceutical corporations developed the ACS GCI Pharmaceutical Roundtable (Roundtable) to encourage innovation while catalyzing the integration of green chemistry and green engineering in the pharmaceutical industry. The activities of the Roundtable reflect the joint belief that the pursuit of green chemistry and green engineering is imperative for a sustainable business and world environment.

Recent News

• New editorial: “Sustainable Manufacturing of Pharmaceutical Industry: The ACS GCI® Pharmaceutical Roundtable,” Rinus Broxterman, Chimica Oggi (Chemistry Today), 27 (5), September-October 2009, p4.
• Special Invitation to Solvent Suppliers: solvent manufacturers are invited to discuss the development of greener solvents at the next ACS GCIPR meeting on October 21, 2009 in Summit, NJ. Please RSVP by October 10.
• Request for Proposals (RFP) now available for the ACS GCI Pharmaceutical Roundtable Research Grant. Deadline Sept. 4, 2009.
• Article by Roundtable Members: “Green Chemistry Articles of Interest to the Pharmaceutical Industry,” Andrews, et al., Organic Process Research & Development 2009 13 (3), 397-408.
• 2008 Year in Review
• “Pharma goes green to cut costs”
• ACS, Pharma Initiative Awards Additional Grant: Joint effort targets more efficient Suzuki C–C coupling reactions that partially avoid halogenated aromatics
• Key green chemistry research areas: A perspective from pharmaceutical manufacturers
• Lessons learned through measuring green chemistry performance
• ACS Pharma Roundtable Award Grant Winners
• Collaboration to deliver a solvent selection guide to the industry

Mission

The Roundtable's mission is to catalyze the implementation of green chemistry and green engineering in the global pharmaceutical industry.

Strategic Priorities

To achieve this mission, the Roundtable identified four strategic priorities:

• Inform and Influence the Research Agenda
• Tools for Innovation
• Education Resource
• Global Collaboration

Open Invitation

The ACS GCI Pharmaceutical Roundtable welcomes the active participation of member companies meeting the following descriptions:

Members

Any corporation, or subsidiary, division or unit thereof, significantly engaged in the manufacture and marketing of finished dosage form ethical pharmaceutical or biological products under his or its own brand names for the cure, alleviation, mitigation, treatment, prevention or diagnosis of disease, and significantly engaged in pharmaceutical, biopharmaceutical or biological research and development of new molecular entities or new therapies, preventative, or in vivo diagnostics, or new systems of therapy, prevention, or diagnosis and who will continue to conduct such research and development.

Associates

Associates shall be corporations, or subsidiaries, divisions or units thereof, not eligible for membership under Members above, who are:

1. Significantly engaged in research and development on their own behalf or as a provider of contract research and development services to companies meeting the definition of Member, directly related to the development or production of ethical pharmaceutical or biological products for the cure, alleviation, mitigation, treatment or prevention of disease.
2. Significantly engaged in the manufacture of intermediates, active pharmaceutical ingredient, or finished dosage form ethical pharmaceutical or biological products.
3. Associates shall have all the rights, privileges and duties prescribed by the Business Plan, and such other rights, privileges and duties as the Management Team may from time to time establish by resolution, except the right to vote.

The ACS Green Chemistry Institute^®, as the convener of the Roundtable, is considered to be a Member with all its rights and privileges.